Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

EdiGene to Discover Stem Cell/Natural Killer CAR Therapy for Neukio

publication date: Feb 9, 2022

Beijing EdiGene and Neukio Biotherapeutics of Shanghai will collaborate to develop next-gen allogenic induced pluripotent stem cell (iPSC) and natural killer cell (NK Cell) CAR therapies. EdiGene will use its high-throughput genome editing screening platform to discover candidates for novel targets, while Neukio will contribute its NK Cell expertise. Formed last year, Neukio completed a $40 million Angel round led by Lilly Asia Ventures. Neukio will develop the cell therapies for specific undisclosed indications. It will make payments to EdiGene upon reaching clinical development milestones and pay royalties on sales. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital